Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg

Gosse, Philippe; Sheridan, Desmond J.; Zannad, Faı̈ez; Dubourg, Olivier; Guéret, Pascal; Karpov, Yuri; Leeuw, Peter Wilhelmus J De; Palma-Gamiz, Jose-Luis; Pessina, Achille; Motz, W.; Degaute, Jean-Paul; Chastang, Claude

doi:10.1097/00004872-200018100-00015

Cited by 178 publications

(85 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The second misconception regarding LVH is that ACE inhibitors are a cure for LVH. This is not the case, as illustrated by both the Left Ventricular Hypertrophy Indapamide Versus Enalapril (LIVE) study [35], in which diuretics were better at reducing left ventricular mass than ACE inhibitors, and also by the Heart Outcomes Prevention Evaluation (HOPE) study [36]. In the LIVE study, treatment with indapamide for 48 weeks significantly reduced left ventricular mass index in hypertensive patients with LVH, whereas enalapril did not.…”

Section: Discussionmentioning

confidence: 99%

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

2005

View full text Add to dashboard Cite

Aims/hypothesis: Patients with type 2 diabetes mellitus are at greater cardiovascular risk than the general population. Although it is widely acknowledged that diabetes is a risk factor for coronary artery disease, the increased prevalence of potentially lethal left ventricular abnormalities in this population is less well appreciated. Methods: We carried out an echocardiographic study of 500 subjects with type 2 diabetes mellitus to assess the prevalence of left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction (LVSD). We also assessed whether abnormalities in diastolic filling parameters were present. Results: Of the 371 patients in whom left ventricular mass could be successfully assessed, 264 had LVH (71%). Left ventricular systolic dysfunction was much less common, being present in 16/385 patients (4.2%). Long axis contraction was abnormal in 29/429 patients (6.8%). Diastolic filling abnormalities were present in 178/435 (41%) of patients who could be classified using the selected criteria. Conclusions: We conclude that left ventricular abnormalities are common in type 2 diabetic patients. As medical therapy is available for both LVH and LVSD and has been demonstrated to reduce cardiovascular death, these left ventricular abnormalities could be ideal targets for screening, followed by selective therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

2005

View full text Add to dashboard Cite

show abstract

“…26 Patients, 20 years old or more and with LVH (LVMI in men 4120 g/m 2 ; LVMI in women 4100 g/m 2 ) and mild to moderate hypertension were included. Two successive selections of echocardiograms were performed per patient.…”

Section: Sbp Lowering In Hypertensive Patients With Left Ventricular mentioning

confidence: 99%

Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure

London¹

2004

J Hum Hypertens

View full text Add to dashboard Cite

The relationship between the increase in blood pressure and the incidence of cardiovascular disease is well recognized today. Studies have shown that more attention should be paid to systolic blood pressure (SBP) in relation to cardiovascular risk and that therapeutic interventions should preferably focus on reducing SBP. The antihypertensive efficacy of indapamide 1.5 mg sustained release (indapamide SR), a lowdose thiazide-type diuretic, was assessed on SBP. Three randomized, double-blind, controlled studies were conducted with indapamide SR, over a period of 3 to 12 months. Elderly patients or patients with target-organ damage, hypertension and left ventricular hypertrophy (LVH) (LIVE study) or with type II diabetes with microalbuminuria (NESTOR study) showed a decrease in SBP varying from 22.7 to 31.8 mmHg. The treatment with indapamide SR resulted in a better or equivalent control of SBP than treatment with a standard dose of a true thiazide diuretic (hydrochlorothiazide), a calcium channel blocker (amlodipine), and an angiotensin-converting enzyme inhibitor (enalapril). No therapeutic escape was observed. All treatments showed good acceptability with no unexpected adverse event. In conclusion, indapamide SR is very effective in lowering SBP-a major independent cardiovascular risk factor-notably in hypertensive high-risk patients with LVH, the elderly and diabetics, when compared to major antihypertensive treatments. This SBP-lowering effect is maintained over the long term.

show abstract

“…32 The current ongoing multicentre study evaluates the long-term treatment strategy based on the very low-dose Per 2 mg/Ind 0.625 mg combination in Controlled study Versus Enalapril in the regression of echocardiographic LVH (PICXEL), in a large population of hypertensive patients. This study which is one of the few which includes optimal design features for such trials combines two originalities: a quality control of all recordings all along the study as performed for the first time in the LIVE study 18 and the use of a dedicated software to measure semi-automatically LVM and reduce interreader variability (Figure 1). …”

Section: Journal Of Human Hypertensionmentioning

confidence: 99%

“…Recently, the LIVE study, conducted in 505 hypertensive patients with LVH, has shown that a full dose of the diuretic indapamide SR 1.5 mg could be significantly more effective than the ACE inhibitor enalapril in reducing LVM inded (LVMI). 18 A very low dose ACE inhibitor/diuretic combination has been proposed as a first-line therapy to improve blood pressure (BP) control in hypertensive patients.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design

et al. 2002

View full text Add to dashboard Cite

The PICXEL study is designed to evaluate the effects of long-term administration of very low-dose combination perindopril 2 mg/indapamide 0.625 mg (Per/Ind) vs enalapril in reducing left ventricular hypertrophy (LVH) in hypertensive patients. This multicentre, controlled, randomised, double-blind, parallel group study is carriedout to assess the variation of left ventricular mass index (LVMI) after treatment, using a centralised control of Mmode echocardiography determinations, and a dedicated software for semi-automatic measurement. Following a 4-week placebo run-in period, hypertensive outpatients aged у18 years, with LVH (LVMI Ͼ120 and 100 g/m 2 for men and women, respectively), are randomised to receive once daily, over 52 weeks, either Per/Ind or enalapril. According to blood pressure levels, the dose may be adjusted. In addition to clinical examinations, ECG, blood pressure, heart rate and laboratory assessments echocardiographic determinations are performed for selection, at baseline, after 24 weeks and

show abstract

Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg

Abstract: Indapamide SR 1.5 mg was significantly more effective than enalapril 20 mg at reducing LVMI in hypertensive patients with LVH.

Cited by 178 publications

References 32 publications

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure

Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design

Contact Info

Product

Resources

About